Eylea is used to treat neovascular (wet) age-related macular degeneration (nAMD) and is FDA-approved for several other eye conditions that involve the retina such as: retinopathy of prematurity (ROP). Eylea is given as an injection into the eye every 1 to 2 months by an eye specialist. Eylea gained FDA approval on November 18, 2011.

EYLEA® HD (aflibercept) Injection 8 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Oct 14, 2024 · Eylea (aflibercept) is a biologic drug prescribed to help prevent vision loss in certain situations. It’s a liquid solution given by healthcare professionals as an injection into the eye. Eylea...

EYLEA® HD (aflibercept) Injection 8 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

EYLEA® HD (aflibercept) Injection 8 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Sep 11, 2024 · Eylea is a drug used to treat wet age-related macular degeneration (AMD). It is also used to treat diabetic eye disease and other problems of the retina. It is injected into the eye to help slow vision loss from these and certain other diseases. Eylea is the brand name for the drug, which is called aflibercept.

EYLEA HD and EYLEA® (aflibercept) Injection are administered by injection into the eye. You should not use EYLEA HD or EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA HD or …

Effective April 1, 2024, EYLEA HD can be billed using the permanent J-code J0177. LEARN MORE. As demonstrated by vision outcomes in PULSAR and PHOTON at Week 48—fewer injections vs EYLEA 2 mg.

View the EYLEA® (aflibercept) Injection results demonstrated across 8 anti-VEGF clinical trials for Wet AMD, DME, DR and MEfRVO. See Important Safety Info and Review Full Prescribing Information.

Jul 8, 2024 · Vabysmo (faricimab) and Eylea (afibercept) are both eye injections used in the treatment of neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). Eylea is also approved to treat diabetic retinopathy (DR) and retinopathy of prematurity (ROP).